Due to the lack of specific molecular targets in TNBC and increased resistance to the anti-HER2 therapies in HER2+ breast tumors, cytotoxic chemotherapy is the common alternative for treating these two most resistant subtypes of BC. The gene discussed is ERBB2; the disease is breast neoplasm.